4.35

3.33% -0.15

After Hours: 4.39 0.04 +0.92%

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $4.35, with a volume of 94,561. It is down -3.33% in the last 24 hours and down -19.44% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

Previous Close:

$4.50

Open:

$4.5

24h Volume:

94,561

Relative Volume:

0.14

Market Cap:

$155.94M

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

-9.19%

1M Performance:

-19.44%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$4.20

$4.50

1-Week Range:

$4.19

$4.80

52-Week Range:

$3.85

$26.62

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1168)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

510-806-1445

Address

1445A SOUTH 50TH STREET, RICHMOND

Employee

Twitter

Next Earnings Date

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	4.35	155.94M	0	0	0	0.00
ZTS Zoetis Inc	165.31	74.02B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.15	45.90B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	14.08	44.64B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.78	19.23B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	128.57	13.67B	612.78M	-86.37M	-62.91M	-0.87

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

09:00 AM

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

09:00 AM

05:00 AM

2025-02-24 | BioAge Labs, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

05:00 AM

04:35 AM

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - TradingView

04:35 AM

03:30 AM

BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit – Hagens Berman - GlobeNewswire

03:30 AM

02:30 AM

Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA - Stockhouse Publishing

02:30 AM

12:09 PM

Lost Money on BioAge Labs, Inc.(BIOA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewswire

12:09 PM

10:30 AM

2025-02-24 | Investors who Lost Money on BioAge Labs, Inc.(BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

10:30 AM

07:30 AM

2025-02-24 | BioAge Labs, Inc. Class Action: Levi & Korsinsky Reminds BioAge Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025BIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

07:30 AM

05:45 AM

The Gross Law Firm Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire

05:45 AM

Feb 23, 2025

BIOA Deadline: BIOA Investors with Losses in Excess of $100K Have Opportunity to Lead BioAge Labs, Inc. Securities Lawsuit - PR Newswire

Feb 23, 2025

Class Action Filed Against BioAge Labs, Inc. (BIOA)March 10, 2025 Deadline to JoinContact Levi & Korsinsky - Stockhouse Publishing

Feb 23, 2025

BIOA IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, - GlobeNewswire

Feb 23, 2025

BIOA IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages BioAge Labs, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BIOA - GlobeNewswire Inc.

Feb 23, 2025

2025-02-23 | BioAge Labs, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before March 10, 2025 to Discuss Your RightsBIOA | NDAQ:BIOA | Press Release - Stockhouse Publishing

Feb 23, 2025

Feb 22, 2025

BIOA CLASS ACTION DEADLINE: BioAge Labs Investors with - GlobeNewswire

Feb 22, 2025

Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - Stockhouse Publishing

Feb 22, 2025

BioAge Labs, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioAge Labs, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit - PR Newswire

Feb 22, 2025

Feb 21, 2025

BioAge Labs, Inc. Sued for Securities Law Violations – - GlobeNewswire

Feb 21, 2025

2025-02-21 | Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:BIOA | Press Release - Stockhouse Publishing

Feb 21, 2025

Deadline Alert: BioAge Labs, Inc. (BIOA) Investors Who Lost - GlobeNewswire

Feb 21, 2025

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of BioAge Labs, Inc.(BIOA) Shareholders - Morningstar

Feb 21, 2025

Feb 20, 2025

Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Stockhouse Publishing

Feb 20, 2025

ROSEN, NATIONAL TRIAL LAWYERS, Encourages BioAge Labs, Inc. Investors to Secure Counsel Before ... - The Bakersfield Californian

Feb 20, 2025

BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference - The Manila Times

Feb 20, 2025